Clinical trial
A Phase III/IV Factorial Randomized Double-blind Trial to Compare the Addition of Dapagliflozin vs Placebo and Rosuvastatin/Ezetimibe Versus Pitavastatin in Patients With HIV on Integrase Strand Transfer Inhibitor-based Antiretrovirals With Elevated Metabolic Risk
NCT06317051 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III/IV Factorial Randomized Double-blind Trial to Compare the Addition of Dapagliflozin vs Placebo and Rosuvastatin/Ezetimibe Versus Pitavastatin in Patients With HIV on Integrase Strand Transfer Inhibitor-based Antiretrovirals With Elevated Metabolic Risk
- Lead sponsor
- Kirby Institute
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 16, 2024
- Completion date
- December 31, 2027
- Enrollment
- 300 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.